The
XELJANZ (tofacitinib) Patient Support Program has been discontinued and is no longer available.
Registration for patient support services is now closed.
This change does
not affect access to XELJANZ® or your prescribed treatment. Your healthcare professional remains your primary point of contact for treatment decisions and ongoing care.
Questions about XELJANZ®:
If you have questions about XELJANZ®, including medical or product‑related enquiries,
Pfizer Medical Information is available to assist you.
Phone: 1800 675 229
Webform: Pfizer Medical Inquiry
Website: Pfizer Medical Information
Please note that Medical Information can provide general medical and scientific information about XELJANZ® but cannot give individual medical advice.
Talk to your healthcare professional
If you have questions about your condition, your treatment plan, or whether XELJANZ® is right for you, please speak with your healthcare professional.
Consumer Medicine Information
For full product and safety information, please refer to the
Consumer Medicine Information (CMI)
available via the
Therapeutic Goods Administration (TGA)
website or from your pharmacist or doctor.
